8-K: Elevation Oncology Transfers Listing to Nasdaq Capital Market, Granted Extension to Regain Compliance

Elevation Oncology's shares will transfer from The Nasdaq Global Select Market to The Nasdaq Capital Market, granting them an extension until September 15, 2025, to regain compliance with Nasdaq's minimum bid price requirement.

Summary

• Elevation Oncology received notice from Nasdaq on September 18, 2024, that it was not in compliance with the minimum bid price requirement, as its shares had been below $1.00 for 30 consecutive business days.
• The company applied to transfer its listing from The Nasdaq Global Select Market to The Nasdaq Capital Market.
• On March 19, 2025, Nasdaq approved the transfer, effective at the opening of business on March 21, 2025.
• The company's shares will continue to trade under the symbol ELEV.
• As a result of the transfer, Elevation Oncology has been granted an additional 180 days, until September 15, 2025, to regain compliance with the minimum bid price requirement.
• To regain compliance, the closing bid price of the company's shares must meet or exceed $1.00 per share for a minimum of 10 consecutive business days on or prior to September 15, 2025.
• The company intends to actively monitor the minimum bid price requirement and consider available options to resolve any deficiencies, including a reverse stock split if necessary.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is facing listing compliance issues, they have been granted an extension and are taking steps to address the problem. The transfer to the Nasdaq Capital Market is a common strategy in this situation.

Positives

• The transfer to The Nasdaq Capital Market is not expected to have any immediate effect on trading in shares of the company's common stock.
• Elevation Oncology has been granted an additional 180 days to regain compliance with the minimum bid price requirement.
• Nasdaq's determination to grant the additional compliance period was in part based on the Company meeting the continued listing requirements of The Nasdaq Capital Market with the exception of the bid price requirement.

Negatives

• Elevation Oncology received a notice from Nasdaq indicating that it was not in compliance with the minimum bid price requirement.
• The company's shares had been trading below $1.00 per share for the previous 30 consecutive business days as of September 18, 2024.

Risks

• There is a risk that Elevation Oncology will not be able to regain compliance with the minimum bid price requirement by September 15, 2025.
• Failure to regain compliance could result in delisting from The Nasdaq Capital Market.
• The company may need to implement a reverse stock split, which could negatively impact shareholders.

Future Outlook

Elevation Oncology intends to continue to actively monitor the minimum bid price requirement and, as appropriate, will consider available options to resolve any deficiencies and regain compliance, including by effecting a reverse stock split if necessary.

Industry Context

Many small-cap biotech companies face challenges in maintaining Nasdaq listing compliance, especially during periods of market volatility or when clinical trial results are delayed or disappointing. A move to the Nasdaq Capital Market is a common strategy to buy time and explore options for improving the stock price.

Comparison to Industry Standards

• Other biotech companies that have faced similar listing compliance issues include companies like XOMA Corporation and Diffusion Pharmaceuticals, which have also implemented reverse stock splits to regain compliance.
• The Nasdaq Capital Market has less stringent requirements than the Global Select Market, allowing companies more flexibility to meet listing standards.

Stakeholder Impact

• Shareholders may experience dilution if a reverse stock split is implemented.
• Employees may be affected by any cost-cutting measures taken to improve the company's financial position.
• The company's ability to raise capital and fund its research and development programs could be impacted if it is delisted from Nasdaq.

Next Steps

• Elevation Oncology will actively monitor the minimum bid price requirement.
• Elevation Oncology will consider available options to resolve any deficiencies and regain compliance.
• Elevation Oncology may effect a reverse stock split if necessary.

Key Dates

Keywords

Nasdaq Capital Market, minimum bid price, listing compliance, ELEV, Elevation Oncology, stock transfer, reverse stock split